<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE296nnn/GSE296381/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296381</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Clonal evolution permits outgrowth of chemoresistant LMPP-like early progenitors in relapsed NPM1c AML</name><description>The most recurrent acute myeloid leukemia (AML) driver in adult patients is a DNA frameshift insertion in the Nucleophosmin 1 (NPM1) gene. This mutation causes a translocation of the coding protein from the nucleus to the cytoplasm (NPM1c). We have generated paired single-cell multi-omics profiles for ~205,000 bone marrow cells collected from NPM1c AML patients at diagnosis and relapse. Detailed single-cell clonal analysis unveiled the evolution, expansion, and concomitant phenotypic changes of pathogenic AML (sub)clones. Blasts with an internal tandem duplication in the FLT3 gene (FLT3-ITD+ blasts) were often lowly abundant at diagnosis but expanded drastically at relapse at the expense of other blasts. Intriguingly, genetically identical FLT3-ITD+ blasts switched from granulocyte-monocyte progenitor-like at diagnosis toward more immature lympho-myeloid primed progenitor (LMPP)-like blasts at relapse. Our data shows that clonal evolution and the accumulation of a FLT3-ITD, is a key evolutionary event that alters AML blast plasticity with minimal changes in the blast phenotype. Increased plasticity favors the specific selection and expansion of FLT3-ITD+ blasts, which adopt a unique LMPP-like phenotype. The overriding transition between diagnosis and relapse suggests that therapeutic interventions (against proliferating cells) could license or accelerate this shift, highlighting the need for a tailored drug composition to target relapsed NPM1c AML.</description><dates><publication>2026/05/01</publication></dates><accession>GSE296381</accession><cross_references><GSM>GSM8969439</GSM><GSM>GSM8969428</GSM><GSM>GSM8969438</GSM><GSM>GSM8969427</GSM><GSM>GSM8969429</GSM><GSM>GSM8969435</GSM><GSM>GSM8969445</GSM><GSM>GSM8969434</GSM><GSM>GSM8969437</GSM><GSM>GSM8969426</GSM><GSM>GSM8969436</GSM><GSM>GSM8969442</GSM><GSM>GSM8969431</GSM><GSM>GSM8969441</GSM><GSM>GSM8969430</GSM><GSM>GSM8969444</GSM><GSM>GSM8969433</GSM><GSM>GSM8969432</GSM><GSM>GSM8969443</GSM><GSM>GSM8969440</GSM><GPL>24676</GPL><GSE>296381</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>